BioCryst Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 8.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.16B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i...